Therefore, we propose rhIL-7-hyFc, a T cell amplifier, as a promising candidate to rescue a compromised antitumor efficacy of PD-1 blockade by restoring the number of PD-1+ tumor-reactive CD8 TILs in T-lymphopenic conditions. Here, CD8A is linked to neoplasm.